1. This application relates to the compound of formula (1), wherein: R1 is an unorthodox group composed of one or two members, selected from the formula group (2)；R2 is hydrogen or halogen, or R1 and R2, together with the carbon atoms connected with them, can form a ring (3) of the formula group；R³ is hydrogen, halogen or lower alkyl； n is the number 1 or 2； R⁴ is phenyl optionally substituted by one or two substituents chosen from halogen or cyano, or is pyridinyl optionally substituted by halogen, or is tetrahydropyran, or is -NH-C (O) -phenyl optionally substituted by halogen； R⁵ is hydrogen or halogen； R⁶-R¹³ are phenyl optionally substituted by halogen； R¹⁴ is -NH-C (O) -phenyl substituted by halogen； R¹⁵ is hydrogen, lower alkyl substituted by halogen or is halogen； R¹⁶ is hydrogen or lower alkoxy； R¹⁷ is pyridinyl optionally substituted by lower alkoxy or lower alkyl substituted by halogen；Or add all acid salts acceptable on the drug, all racemic mixtures, all of their corresponding corresponding isomers and / or optical isomers, and all of the Dow (1) of the formula compound. Formula compound (1) has good affinity with the receptor of trace amine (Taar),Especially the terry These compounds can be used to treat depression, anxiety, bipolar disorder, attention deficit hyperactivity disorder (ADHD),Diseases related to stress, psychosis, schizophrenia, neurological diseases, Parkinson's disease, neurodegenerative diseases, Alzheimer's disease, epilepsy, migraine, hypertension, drug abuse, metabolic disorders, Eating disorders, diabetes, diabetic complications, obesity, defatting, energy intake and digestion disorders, body temperature homeopathy and abnormalities, sleep and cirrhosis disorders, and cardiovascular diseases.La presente se refiere a compuestos de la fórmula (1) en la que: R¹ es un grupo heteroarilo de uno o dos miembros, elegido entre el grupo de fórmulas (2)； R² es hidrógeno o halógeno； o R¹ y R² junto con el átomo de carbono, al que están unidos,
